Tango Therapeutics

Edit info

Founded: 2016

Location: Cambridge, MA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Oncology

Drug types: ONC

Lead product: TNG908

Funding: $80M stock Aug 2023; $50M Aug 2020; $60M B Apr 2020; $55M Mar 2017

tangotx.com

linkedin.com

job board

Business:

Cancer Therapeutics, Immuno-Oncology

Drug notes:

TNG462 Clin1/Clin2 oncology; TNG260 Clin1/Clin2 oncology; TNG348 Clin0 cancers

About:

Tango Therapeutics is using the principle of synthetic lethality to develop medicines for cancer patients. Synthetic lethality describes a situation where loss of two targets results in cell death, while loss of either one alone does not. Since some tumors already possess target loss, Tango is using their CRISPR-based functional genomics target discovery platform and analytic pipeline to identify novel synthetic lethal targets that can selectively kill tumor cells. Tango is applying this approach in two core areas: [1] tumor suppressor gene loss and [2] immune evasion. Once targets are identified, Tango screens for drugs that have therapeutic potential. Tango’s lead candidate, TNG908, is being evaluated in clinical trials for MTAP-deleted tumors.